Updated on 17 October 2012
Resverlogix initiates pre-diabetes mellitus phase II trial to examine RVX-208 and ApoA-I
Singapore: Resverlogix has initiated an exploratory phase II clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism.
The trial is conducted in collaboration with Baker IDI Heart and Diabetes Institute in Melbourne, Australia, and it will examine insulin secretion, insulin sensitivity and other parameters of importance in individuals with pre-diabetes mellitus. Twenty patients will be enrolled in Australia, with data expected in the first half of 2014.
Increased abundance of insulin in subjects with pre-diabetes mellitus may prevent or substantially delay the progression towards diabetes mellitus. The estimated trial expense will be less than $1MM CDN with an approximate split in costs of 50/50 between Resverlogix and the Baker IDI Heart & Diabetes Institute.
"Diabetes mellitus is the most common endocrine disease in the world," said Dr Norman Wong, CSO, Resverlogix. "The prevalence of this disease is rising at epidemic rates. A primary defect in diabetes mellitus is that the patient's pancreas cannot provide enough insulin for the body, thus leading to increased blood glucose levels. Diabetes mellitus can lead to severe sequelae such as kidney disease, heart disease, disorders of the nerves and blindness.